Lemborexant Pill
Phase 2
Lemborexant Pill is one of 8 therapeutic programs targeting Post-Operative Delirium. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
7
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
9 competitors in Post-Operative Delirium
#DrugCompanyPhaseTrials
1Exelon
NovartisApproved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Cymbalta
Jazz PharmaceuticalsApproved
Haldol
DDePuy Orthopaedics
Approved
Dayvigo
EisaiPhase 2
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Lemborexant Pill
BBeijing Tiantan Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Lemborexant Pill. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- BBeijing Tiantan Hospital